<DOC>
	<DOCNO>NCT00000421</DOCNO>
	<brief_summary>The first part study use database large , ongoing NIH-sponsored lupus study , Safety Estrogen Lupus Erythematosus National Assessment . We examine level blood protein know C3a series patient blood sample see C3a level predict lupus flare well blood test , therefore use widely manage lupus . In second part study add increase prednisone treatment basis abnormality blood test C3a dsDNA antibody . Early treatment base increase C3a dsDNA antibody , patient develop physical sign disease , may reduce lupus flare , ultimately , patient 's total steroid exposure . We follow study participant 1 year monthly basis full physical examination laboratory evaluation . If C3a dsDNA antibody level increase significantly baseline level patient clinically stable , give patient either prednisone inactive pill ( placebo ) 1 month . We follow patient monthly compare often lupus flare occur two group . This approach could provide novel method prevent lupus flare , use C3a sensitive predictor flare .</brief_summary>
	<brief_title>Serologically Active , Clinically Stable Systemic Lupus Erythematosus</brief_title>
	<detailed_description>In lupus , serial evaluation dsDNA antibody titer complement ( C3 C4 ) blood sample useful assess disease activity patient . High level C3a , split product C3 , particularly sensitive reflective lupus flare . Our study look whether elevation C3a predict lupus flare C3a compare conventional blood indicator dsDNA antibody , C3 , C4 , CH50 . The utility serial anti-dsDNA antibody complement measurement clinical decision-making people systemic lupus erythematosus ( SLE ) remain controversial . This study two specific part design address issue . In first , take advantage unique opportunity collaborate large , multicenter NIH-sponsored protocol , Safety Estrogens Systemic Lupus National Assessment ( SELENA ) trial . We perform observational study approximately 1,000 woman enrol SELENA trial ass sensitivity , specificity , predictive value anti-dsDNA antibody , C3 , C4 , CH50 , C3a desArg . Using samples patient enrol SELENA study , perform subgroup analysis diverse ethnic group , patient treat exogenous estrogen , patient chronically depressed CH50 . In second-an interventional study-we evaluate effectiveness short-term corticosteroid treatment avert flare elevation plasma C3a accompany rise anti-dsDNA antibody . We determine whether corticosteroid treatment reduces frequency clinical flare , serological abnormality , disease activity inactive stable patient . We explore whether steroid disproportionately exacerbate initiate comorbid medical condition ( e.g. , hypertension , diabetes ) may prevalent among minority patient . The study result observation lead rational , cost-effective , evidence-based guideline improve treatment patient SLE and-by decrease morbidity disease-result significant improvement quality life .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Meets ACR criterion SLE Inactive stable lupus activity History positive dsDNA Current prednisone dose 15 mg daily Active infection Poorly control diabetes mellitus Pregnancy Uncontrolled hypertension</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Anti-double-stranded DNA antibody</keyword>
	<keyword>Corticosteroid treatment</keyword>
	<keyword>Hormone therapy</keyword>
	<keyword>Complement</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Estrogen</keyword>
	<keyword>SELENA</keyword>
</DOC>